Halozyme (HALO) Q3 2026 Earnings Call Transcript

Halozyme reported Q3 2026 revenue of $493 million, up 39% year over year, and record royalty revenue of $341 million, up 44%; adjusted EBITDA rose 35% to $336.2 million. It raised 2026 revenue guidance to $1.86 billion–$1.925 billion and non-GAAP diluted EPS guidance to $8.75–$9.05, citing year-to-date performance and royalty strength. The Dutch court prohibited Merck-related infringement of Halozyme’s EP622 patent in eight European countries, while management said U.S. patent proceedings have had adverse validity decisions and are subject to appeal. Halozyme also reported $400 million in share repurchases through the first nine months of 2026.

Analysis

The important signal is not simply faster IV-to-SC switching: new-patient starts suggest SC can expand the treated market by bypassing infusion-capacity and site-of-care constraints. That creates upside for Halozyme’s royalty base and partner franchises, but makes the portfolio less independent than its product count implies: multiple streams rely on SC adoption, partner execution and durable delivery patents. A slowdown in that shared mechanism could hit several royalty lines together.

Near term, the guidance raise supports earnings visibility, but the incremental change is modest relative to the scale of the business; the larger valuation debate is whether newer launches can offset the anticipated DARZALEX royalty step-down around 2029–30. OCREVUS ZUNOVO and OPDIVO Qvantig conversion, plus RYBREVANT FASPRO uptake, are the measurable bridge. Pipeline additions and Hypercon/Aerocon remain long-dated options, not near-term earnings proof; the cited Hypercon royalty opportunity is management’s projection, with clinical starts only expected in 1H27.

The European ruling is meaningful leverage against Merck, but not a read-through to U.S. rights: the patents and proceedings differ, U.S. outcomes remain adverse so far, and the appeal path may run to 2028. Do not price the European injunction as a global supply block or settlement. Convertible financing alongside buybacks also warrants scrutiny: repurchases may support per-share results, but do not eliminate debt or potential dilution. The contrarian risk is that strong current royalties obscure concentrated adoption and patent-duration risks; the bullish case is that SC adoption is expanding demand, not merely changing administration route.

Key Decisions for Investors

• Treat Halozyme as a staged long/watch rather than chase the post-call move: add only if price action leaves a margin of safety against the 2029–30 DARZALEX step-down. Reassess when February 2027 guidance quantifies the royalty bridge; falsify the thesis if partner conversion or royalty growth materially decelerates.
• Track quarterly conversion and new-start mix for OCREVUS ZUNOVO and OPDIVO Qvantig, and SC uptake for RYBREVANT FASPRO. If conversion stalls or partner growth weakens, reduce exposure: that would challenge the market-expansion thesis and the assumed offset to legacy royalty erosion.
• Keep Merck litigation as event-driven optionality, not a standalone short thesis. The European injunction is geographically limited and U.S. proceedings remain distinct; revisit only on an appeal ruling, a material U.S. patent decision, or independently confirmed supply impact.
• Do not assign material near-term value to Hypercon/Aerocon. Upgrade the option value only after the planned 1H27 clinical starts and evidence on PK, tolerability and manufacturability; delays to clinical supply or starts would weaken the long-dated growth case.